Cargando…
Utility of (18)F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
BACKGROUND: Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) is a predictor of improved outcomes in breast cancer. In patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative breast cancer, the response to NAC is variable and most...
Autores principales: | Lee, In Hee, Lee, Soo Jung, Lee, Jeeyeon, Jung, Jin Hyang, Park, Ho Yong, Jeong, Shin Young, Lee, Sang-woo, Chae, Yee Soo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667770/ https://www.ncbi.nlm.nih.gov/pubmed/33198673 http://dx.doi.org/10.1186/s12885-020-07505-w |
Ejemplares similares
-
Early Assessment of Response to Neoadjuvant Chemotherapy with (18)F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer
por: Chung, Young Shin, et al.
Publicado: (2020) -
Prognostic value of complete metabolic response on (18)F-FDG-PET/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer
por: Chung, Young Shin, et al.
Publicado: (2022) -
Development and External Validation of (18)F-FDG PET-Based Radiomic Model for Predicting Pathologic Complete Response after Neoadjuvant Chemotherapy in Breast Cancer
por: Lim, Chae Hong, et al.
Publicado: (2023) -
Oncologic necessity for the complete removal of residual microcalcifications after neoadjuvant chemotherapy for breast cancer
por: Lee, Jeeyeon, et al.
Publicado: (2022) -
Prediction of Advanced Axillary Lymph Node Metastases (ypN2-3) Using Breast MR imaging and PET/CT after Neoadjuvant Chemotherapy in Invasive Ductal Carcinoma Patients
por: Kim, Won Hwa, et al.
Publicado: (2018)